FTO regulates osteoclast development by modulating the proliferation and apoptosis of osteoclast precursors in inflammatory conditions

• Published in: Cellular signalling Vol. 117; p. 111098
• Main Authors: He, Jinlin, Zhao, Yiqing, Zhang, Yiwen, Zhang, Zhanqi, Li, Di, Xu, Qiong
• Format: Journal Article
• Language: English
• Published: England Elsevier Inc 01.05.2024
• Subjects: Bone resorption; FTO; m6A; Osteoclast precursor cells; Periodontitis; FTO; Bone resorption; m6A; Osteoclast precursor cells; Periodontitis; mA
• ISSN: 0898-6568; 1873-3913
• DOI: 10.1016/j.cellsig.2024.111098

Periodontitis is an oral inflammatory disease that causes alveolar bone destruction by activating osteoclast. FTO, a crucial demethylase of N6-methyladenosine(m6A), exerts essential function in maintaining bone homeostasis. However, the effects of FTO on periodontitis-related bone destruction remain unknown. To investigate its role in inflammatory osteoclastogenesis, we overexpressed FTO in osteoclast precursor cells; RNA-seq revealed that differentially expressed genes were mainly enriched in cell cycle, DNA replication, DNA damage response and apoptosis in FTO overexpression cells during RANKL and LPS-stimulated osteoclast differentiation. FTO overexpression upregulated the expression of S phase-related proteins (Cyclin A2, CDK2), and decreased the expression of DNA damage related proteins in osteoclast precursor cells. FTO promoted cell proliferation demonstrated by EdU and CCK8 assay, and reduced apoptotic rate and the expression of apoptosis-related proteins in osteoclast precursor cell. Conversely, FTO inhibitor FB23-2 produced the reverse effect. Mechanistically, FTO overexpression promoted the stability of CyclinA2 and CDK2 mRNA. These results were consistent in m6A binding protein YTHDF2 knockdown cells. Moreover, FB23-2 suppressed osteoclast-related gene expression, osteoclast formation and bone resorption ability. Treatment of FB23-2 reduced the alveolar bone loss in mice of experimental periodontitis. Collectively, our findings revealed that FTO enhanced the mRNA stability and expression of Cyclin A2, CDK2 in a YTHDF2-dependent manner in osteoclast precursor cells, promoted cell proliferation and inhibited cell apoptosis. FB23-2 reduced the formation of osteoclasts, resulted in alleviating the bone destruction in periodontitis mice. These findings indicated that FTO might be the potential target of the treatment of bone loss in periodontitis. •FTO regulated cell cycle and DNA damage during inflammatory osteoclastogenesis.•FTO enhanced the proliferation and prevented the apoptosis of osteoclast precursors.•FTO decreased CDK2 and Cyclin A2 mRNA degradation through a YTHDF2-dependent manner.•FTO inhibitor FB23-2 suppressed osteoclast formation and bone resorption ability in vitro.•FB23-2 reduced the bone resorption and osteoclast formation in experimental periodontitis mice.